Canadian Journal of Gastroenterology and Hepatology

Nonalcoholic Fatty Liver Disease


Status
Published

1University of Belgrade, Belgrade, Serbia

2University of East Anglia, Norwich, UK

3Diagnostični Center Rogaška, Rogaška Slatina, Slovenia

4Universitatea de Medicina si Farmacie Iuliu Hatieganu din Cluj-Napoca, Cluj-Napoca, Romania


Nonalcoholic Fatty Liver Disease

Description

Nonalcoholic fatty liver disease (NAFLD) is regarded as the most significant liver disease from the twenty-first century in the Western world. Although its development is surely driven by environmental factors, it is also regulated by genetic background. NAFLD ranges over a wide spectrum, extending from nonalcoholic fatty liver (NAFL) which is generally benign, through nonalcoholic steatohepatitis (NASH) to liver cirrhosis, end-stage liver disease, and even hepatocellular carcinoma (HCC) despite the absence of significant alcohol consumption. The relationship of NAFLD with metabolic alterations such as type 2 diabetes is well described and related to insulin resistance, with NAFLD being recognized as the hepatic manifestation of metabolic syndrome. However, NAFLD may also coincide with endocrine diseases such as polycystic ovary syndrome, hypothyroidism, growth hormone deficiency, or hypercortisolism. It is therefore essential to remember, when discovering altered liver enzymes or hepatic steatosis on radiological exams, that endocrine diseases can cause NAFLD. In the latest years, obstructive sleep apnea syndrome (OSAS) has been associated NAFLD. Experimental evidence suggests that chronic intermittent hypoxia may per whole trigger liver injury, inflammation, and fibrogenesis, and, interestingly, OSAS is also believed to be one of the elements promoting the evolution of NAFLD from steatosis to nonalcoholic steatohepatitis (NASH).

We invite investigators to contribute original research articles as well as review articles that will stimulate the continuing efforts to understand the complex pathophysiology of NAFLD. Our particular attention is paid to the relationship between NAFLD and endocrine dysfunctions, as well as to NAFLD involvement with OSAS, risk estimation of NAFLD patients for cardiovascular diseases, psychological impairments in NAFLD patients, novelties in the diagnostics and therapy of NAFLD and concomitant diseases, dietary approaches in the NAFLD treatment, and so forth.

Potential topics include but are not limited to the following:

  • Epidemiology
    • NAFLD in general population
    • NAFLD in pediatric population
  • Etiology
    • Oxidative stress and NAFLD
    • Genetic background in NAFLD
    • Endocrine causes of NAFLD
  • Pathology
    • Determination of nuclear receptors in NAFLD
    • Psychosocial factors in NAFLD pathogenesis
    • Inflammatory markers on NAFLD
    • Insulin resistance and NAFLD
  • Diagnosis
    • Noninvasive scoring system for NAFLD prediction
    • MRI elastography accuracy in NAFLD
    • Novel serum biomarkers for NAFLD
    • Histological evaluation of NAFLD
    • Ultrasonography role in NAFLD diagnosis and evaluation
  • Comorbidity
    • Comorbidity of NAFLD and OSAS
    • NAFLD and metabolic X syndrome
    • NAFLD and diabetes mellitus type 2
    • NAFLD and chronic kidney disease
    • Cardiovascular diseases and disorders and NAFLD
    • PCO syndrome and NAFLD
  • Treatment
    • Life style and dietary interventions in the management of NAFLD
    • Pharmacotherapy of NAFLD
    • Effectiveness of exercise for hepatic fat mobilization in NAFLD
    • Immunological approaches to NAFLD
    • Psychological and psychiatric components in NAFLD treatment
    • Guidelines, ambiguities, and pitfalls of the NAFLD therapy in pediatric patients
    • Effects of bariatric surgery on liver functions and NAFLD

Articles

  • Special Issue
  • - Volume 2018
  • - Article ID 2097435
  • - Editorial

Nonalcoholic Fatty Liver Disease

Branka Filipović | Alastair Forbes | ... | Dan L. Dumitraşcu
  • Special Issue
  • - Volume 2018
  • - Article ID 9465784
  • - Research Article

Predictive Value of Adiposity Level, Metabolic Syndrome, and Insulin Resistance for the Risk of Nonalcoholic Fatty Liver Disease Diagnosis in Obese Children

Zofia Prokopowicz | Ewa Malecka-Tendera | Pawel Matusik
  • Special Issue
  • - Volume 2018
  • - Article ID 1053710
  • - Clinical Study

The Effects of Extra Virgin Olive Oil on Alanine Aminotransferase, Aspartate Aminotransferase, and Ultrasonographic Indices of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Patients Undergoing Low Calorie Diet

Farzad Shidfar | Samaneh Sadat Bahrololumi | ... | Ali Mohammadimanesh
  • Special Issue
  • - Volume 2018
  • - Article ID 5016091
  • - Clinical Study

The Relationship between NAFLD and Sarcopenia in Elderly Patients

Yu Zhai | Qian Xiao | Jing Miao
  • Special Issue
  • - Volume 2018
  • - Article ID 5323061
  • - Research Article

Speculation of the Time-Dependent Change of FIB4 Index in Patients with Nonalcoholic Fatty Liver Disease: A Retrospective Study

Hiroshi Miyata | Satoru Miyata
  • Special Issue
  • - Volume 2018
  • - Article ID 9638797
  • - Research Article

Cognitive Changes and Brain Volume Reduction in Patients with Nonalcoholic Fatty Liver Disease

Branka Filipović | Olivera Marković | ... | Branislav Filipović
  • Special Issue
  • - Volume 2017
  • - Article ID 6070135
  • - Research Article

Diagnostic Accuracy of Platelet Count and Platelet Indices in Noninvasive Assessment of Fibrosis in Nonalcoholic Fatty Liver Disease Patients

Tamara Milovanovic Alempijevic | Milica Stojkovic Lalosevic | ... | Tomica Milosavljevic
  • Special Issue
  • - Volume 2017
  • - Article ID 4697194
  • - Research Article

Outcomes following Serial Intragastric Balloon Therapy for Obesity and Nonalcoholic Fatty Liver Disease in a Single Centre

Vi Nguyen | Jiawei Li | ... | Jude A. Oben
Canadian Journal of Gastroenterology and Hepatology
 Journal metrics
Acceptance rate26%
Submission to final decision79 days
Acceptance to publication42 days
CiteScore1.420
Impact Factor1.714
 Submit

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.